These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 31197526

  • 1. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, Haq R, Kirpalani A, Chan KKW, Petrella TM, Brezden-Masley C.
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [Abstract] [Full Text] [Related]

  • 2. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Graham JJ, Chow CM, Thavendiranathan P, Dai D, Ng MY, Barfett JJ, Connelly KA, Yan AT.
    Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
    [Abstract] [Full Text] [Related]

  • 3. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
    Barthur A, Brezden-Masley C, Connelly KA, Dhir V, Chan KK, Haq R, Kirpalani A, Barfett JJ, Jimenez-Juan L, Karur GR, Deva DP, Yan AT.
    J Cardiovasc Magn Reson; 2017 Apr 10; 19(1):44. PubMed ID: 28395671
    [Abstract] [Full Text] [Related]

  • 4. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
    Song L, Brezden-Masley C, Ramanan V, Ghugre N, Barfett JJ, Chan KKW, Haq R, Petrella T, Dhir V, Jimenez-Juan L, Chacko BR, Kotha V, Connelly KA, Yan AT.
    Am J Cardiol; 2019 Apr 01; 123(7):1173-1179. PubMed ID: 30683420
    [Abstract] [Full Text] [Related]

  • 5. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, Khanfir A.
    Am J Clin Oncol; 2020 Jul 01; 43(7):510-516. PubMed ID: 32304433
    [Abstract] [Full Text] [Related]

  • 6. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.
    Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, Klem I, Farzaneh-Far A, Shenoy C.
    J Cardiovasc Magn Reson; 2017 Mar 24; 19(1):34. PubMed ID: 28335788
    [Abstract] [Full Text] [Related]

  • 7. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
    Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, Summers AR, Singal PK, Barac I, Kirkpatrick ID, Jassal DS.
    J Clin Oncol; 2010 Jul 20; 28(21):3429-36. PubMed ID: 20530277
    [Abstract] [Full Text] [Related]

  • 8. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
    Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Chow CM, Thavendiranathan D, Haq R, Barfett JJ, Petrella TM, Connelly KA, Yan AT.
    Int J Cardiol; 2018 Jun 15; 261():228-233. PubMed ID: 29555336
    [Abstract] [Full Text] [Related]

  • 9. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, Amir E, Brezden-Masley C, Koch CA, Thevakumaran Y, Yan AT, Marwick TH, Wintersperger BJ, Thavendiranathan P.
    JACC Cardiovasc Imaging; 2021 May 15; 14(5):962-974. PubMed ID: 33248962
    [Abstract] [Full Text] [Related]

  • 10. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
    Bergamini C, Niro L, Springhetti P, Ferri L, Trento L, Minnucci I, Maffeis C, Tafciu E, Rossi A, Fiorio E, Benfari G, Ribichini F.
    Cardiovasc Toxicol; 2024 Jun 15; 24(6):550-562. PubMed ID: 38696070
    [Abstract] [Full Text] [Related]

  • 11. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J.
    JACC Heart Fail; 2019 Sep 15; 7(9):795-804. PubMed ID: 31401102
    [Abstract] [Full Text] [Related]

  • 12. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).
    Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, Meekes MR, de Haan AF, Tol J, Maas AH, Elias-Smale SE, de Geus-Oei LF.
    J Nucl Cardiol; 2016 Aug 15; 23(4):824-32. PubMed ID: 26048264
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.
    J Am Coll Cardiol; 2011 May 31; 57(22):2263-70. PubMed ID: 21616287
    [Abstract] [Full Text] [Related]

  • 15. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy.
    Jolly MP, Jordan JH, Meléndez GC, McNeal GR, D'Agostino RB, Hundley WG.
    J Cardiovasc Magn Reson; 2017 Aug 02; 19(1):59. PubMed ID: 28768517
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
    Thavendiranathan P, Shalmon T, Fan CS, Houbois C, Amir E, Thevakumaran Y, Somerset E, Malowany JM, Urzua-Fresno C, Yip P, McIntosh C, Sussman MS, Brezden-Masley C, Yan AT, Koch CA, Spiller N, Abdel-Qadir H, Power C, Hanneman K, Wintersperger BJ.
    JAMA Cardiol; 2023 Jun 01; 8(6):524-534. PubMed ID: 37043251
    [Abstract] [Full Text] [Related]

  • 17. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
    Bouwer NI, Liesting C, Kofflard MJM, Brugts JJ, Kock MCJ, Kitzen JJEM, Levin MD, Boersma E.
    Cardiovasc Ultrasound; 2021 Nov 09; 19(1):35. PubMed ID: 34753503
    [Abstract] [Full Text] [Related]

  • 18. Comparing left ventricular ejection fraction measurement using cardiovascular magnetic resonance imaging.
    Luk WH, Au-Yeung AW, Lo AX, Loke TK, Ng TW.
    Radiol Technol; 2014 Nov 09; 85(5):494-9. PubMed ID: 24806052
    [Abstract] [Full Text] [Related]

  • 19. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
    Blancas I, Martín-Pérez FJ, Garrido JM, Rodríguez-Serrano F.
    Breast; 2020 Dec 09; 54():106-113. PubMed ID: 32977298
    [Abstract] [Full Text] [Related]

  • 20. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.
    Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, Fresno CU, Somerset E, Amir E, Marwick TH, Wintersperger BJ, Thavendiranathan P.
    Heart; 2020 Jun 09; 106(11):817-823. PubMed ID: 32098808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.